文献速递骨软组织肉瘤与黑色素瘤

肢端部位黑色素瘤的临床与遗传学分析

Clinical and genetic analysis of melanomas arising in acral sites.
PubMed 文献 · Eur J Cancer · 2019-08-14

该研究回顾性分析了134例肢端黑色素瘤患者的临床病理特征及治疗反应,并对50例样本进行靶向二代测序。常见突变为BRAF(30%)、NRAS(28%)、TERT启动子(26%)、NF1(14%)和KIT(6%),且掌跖与背侧肢端部位的突变频率存在差异。一线免疫检查点抑制剂治疗的总生存期长于其他系统治疗。

要点

  • 肢端黑色素瘤常见BRAF、NRAS、TERT启动子、NF1和KIT突变。
  • 掌跖与背侧肢端黑色素瘤的NRAS、NF1、BRAF和TERT启动子突变频率不同。
  • 一线免疫检查点抑制剂治疗的总生存期优于其他系统治疗。

核心结论

  • 肢端黑色素瘤的遗传学特征随肿瘤部位变化,并可能影响生物学行为。

研究设计与样本

  • 回顾性收集并分析德国埃森皮肤科134例肢端黑色素瘤患者的临床数据,评估临床病理特征和治疗反应。
  • 对50例样本进行靶向二代测序的遗传学分析。

主要发现

  • 队列中BRAF突变占30%,NRAS突变占28%,TERT启动子突变占26%,NF1突变占14%,KIT突变占6%。
  • 掌跖黑色素瘤与背侧肢端黑色素瘤相比,NRAS突变频率为39.1% versus 25%,NF1为17.3% versus 0%,BRAF为21.7% versus 75%,TERT启动子为8.6% versus 50%。
  • 64%的肿瘤中识别出MAPK激活突变。
  • 一线免疫检查点抑制剂治疗患者的总生存期长于接受其他系统治疗(BRAF/MEK抑制剂和化疗)的患者。

临床怎么用

  • 肢端黑色素瘤患者可考虑进行包括BRAF、NRAS、TERT启动子、NF1和KIT在内的基因检测。
  • 一线系统治疗时,免疫检查点抑制剂可能带来更长的总生存期。

局限性

  • 遗传学分析仅基于50例样本,样本量有限。
  • 研究为单中心回顾性分析,治疗反应数据可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY AIM: Melanomas arising in acral sites are associated with a poorer prognosis than other melanoma subtypes. The aim of this study was to evaluate clinical-pathological and genetic characteristics as well as therapeutic responses of a larger cohort of patients with melanomas arising in acral sites. METHODS: Clinical data of 134 patients with melanomas arising in acral sites from the Dept. of Dermatology Essen were collected and analysed with regard to clinicopathological characteristics and treatment responses. Genetic analysis with targeted next-generation sequencing was done on 50 samples. RESULTS: In our cohort, BRAF (30%), NRAS (28%), TERT promoter (26%), NF1 (14%) and KIT (6%) were frequently identified mutations. Comparing tumours situated on palms and soles with melanomas arising on dorsal acral sites, a higher frequency of NRAS (39.1% versus 25%) and NF1 (17.3% versus 0%) and lower frequencies of BRAF (21.7% versus 75%) and TERT promoter (8.6% versus 50%) mutations were observed. MAPK activating mutations were identified in 64% of tumours. Overall survival was longer in patients treated with immune checkpoint inhibitors as first-line treatment than in patients receiving other systemic therapies (i.e. BRAF/MEK inhibitors and chemotherapy). CONCLUSION: Our data suggest that the genetics of melanomas arising in acral sites varies by tumour location and may influence biological behaviour.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zaremba A, Murali R, Jansen P, et al. Clinical and genetic analysis of melanomas arising in acral sites. Eur J Cancer. 2019. PMID: 31419753. doi:10.1016/j.ejca.2019.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。